Adaptive Biotechnologies Corporation is rated Hold as MRD segment momentum offset by competitive & valuation concerns. Read ...

The move will dilute the Seattle company's ownership in the subsidiary from 70% to less than 50%, according to the filing.

SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

The S&P healthcare index (XLV) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, though it fell ...

About 100 workers are being laid off as Adaptive Biotechnologies reorganizes its business, homing in on just two core areas of healthcare that can be served by its immune system-focused genetic ...

Adaptive Biotechnologies’ management is scheduled to present on Monday, January 12, 2026, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access a live and archived webcast ...

SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...

Adaptive Biotechnologies ( ($ADPT) ) has issued an announcement. On December 30, 2025, Adaptive Biotechnologies announced that its 70%-owned ...

Adaptive Biotechnologies (NASDAQ: ADPT), a company that, in its own words, "aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease," was the ...

The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. The commercial-stage Adaptive booked $58.9 ...

Adaptive moved into its new headquarters in September. Co-founders Harlan (left) and Chad Robins on the new plaza. (GeekWire Photo / Charlotte Schubert) Adaptive Biotechnologies, which develops ...

On a relatively sleepy day for the market, the biotech enjoyed a decent little price pop on earnings. Its first quarter results topped analyst estimates on both the top and bottom lines. A double beat ...